Drug giants Johnson & Johnson and Novartis colluded to delay the availability of a less expensive generic version of a powerful medication often used to ease severe pain in cancer patients. http://www.nytimes.com/2013/02/01/business/global/eu-says-drug-makers-paid-to-delay-generic-version.html?ref=world&_r=0 EU antitrust chief said on Thursday that the money probably changed hands to keep lower-cost versions of the drug off the market in the Netherlands and that is illegal when it involves a payment from the brand-name company to the generic company.